

# Jaime Sanz-Cnovas

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8963235/jaime-sanz-cnovas-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

7

papers

43

citations

2

h-index

6

g-index

12

ext. papers

80

ext. citations

3.8

avg, IF

1.91

L-index

| # | Paper  | IF  | Citations |
|---|--|-----|-----------|
| 7 | Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study. <i>Annals of Medicine</i> , <b>2019</b> , 51, 252-261     | 1.5 | 15        |
| 6 | Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2021</b> , | 0.9 | 14        |
| 5 | Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure. <i>Journal of the American Geriatrics Society</i> , <b>2021</b> ,                                     | 5.6 | 2         |
| 4 | Statin Therapy in Very Old Patients: Lights and Shadows.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 779044  | 5.4 | 2         |
| 3 | Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,        | 4.6 | 2         |
| 2 | Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,                           | 5.1 | 2         |
| 1 | De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,                       | 5.1 | 1         |